|ISSUE BRIEFS & REPORTS|
PPC has been at the forefront of the growing momentum behind academic detailing. Academic detailing, also known as prescriber education, is the practice of sending independent, highly trained clinicians into prescribers’ practices in order to discuss the best, most scientifically rigorous, comparative information on prescription drugs.
In 2008, PPC undertook a major initiative, the Academic Detailing Planning Initiative, to engage leaders in Maine, New Hampshire, and Vermont in a collaborative inquiry into how states can work together on prescriber education programs in order to maximize their impact while minimizing program costs. This inquiry produced a guidance document, A Template for Establishing and Administering Prescriber Support and Education Programs, which has drawn the attention of the American Medical Association and the Agency for Healthcare Research and Quality, as well as other states with emerging programs.
PPC has also developed an Academic Detailing Toolkit to serve as a resource for learning about and establishing academic detailing (prescriber education) programs. The toolkit includes best practices, fact sheets, presentations, and other materials.
The Maine Center for Economic Policy recently published an issue brief, Choices, that focuses on academic detailing. A New Kind of House Call Delivers Science Not Sales: Prescription Drug Reform That Works, written by PPC policy analyst Jennifer Reck, examines ways to curb undue industry influence, promote evidence-based prescribing, and contain prescription drug costs.
NEW! AARP REPORT
Academic Detailing in Practice: A Tale of Four States (PDF, 362 KB)
The AARP Rx Watchdog Report gives an overview of academic detailing, with an interview with Jerry Avorn, the Harvard professor of medicine who first envisioned it, and looks at academic detailing in a number of states, including Maine, where PPC has been directly involved.
Published by the Maine Center for Economic Policy and written by PPC policy analyst Jennifer Reck, this issue brief examines ways to curb undue industry influence, promote prescriber education, and contain prescription drug costs.